×
Log in
Get Started
Travel
Technology
Sports
Marketing
Education
Career
Social Media
+ Explore all categories
Report -
Trifluridina / Tipiracilo en tercera línea de cáncer ... · Regorafenib posterior 10 % Beneficio clínico radiológico 34 % Progresión 86 % Exitus 57 % Las variables cuantitativas
Select
Pornographic
Defamatory
Illegal/Unlawful
Spam
Other Terms Of Service Violation
File a copyright complaint
Please pass captcha verification before submit form